These results provide evidence for a new mechanism to improve ICIs by targeting the pro-survival functions of MCL1 in myeloid cells, thus effectively decreasing the frequency of immunosuppressive MDSCs within the tumor microenvironment. The gene discussed is MCL1; the disease is neoplasm.